Teledermatology in a rural area of southern Spain: A 12‐year study

Abstract

521–5. 3. Chan LC, Chaili S, Filler SG et al. Nonredundant roles of Interleukin-17A (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun. 2015; 83: 4427– 37. 4. Das S, Khader S. Yin and yang of interleukin-17 in host immunity to infection. F1000Res. 2017; 23(6): 741. 5. Zhang L, Yang H, Chen Q et al. Adverse drug events observed with 150 mg versus 300 Mg secukinumab for the treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e14042. 6. Rompoti N, Sidiropoulou P, Panagakis P et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J. Eur. Acad. Dermatol. Venereol. 2020; 34: 1240–7. 7. Ortiz-Salvador JM, Saneleuterio-Temporal M, MagdalenoTapial J et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J. Am. Acad. Dermatol. 2019; 81: 427–32. 8. Ger TY, Huang YH, Hui RCY et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther. Adv. Chronic Dis. 2019; 17(10): 20406223 19843756. 9. Deodhar A, Mease PJ, McInnes IB et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res. Ther. 2019; 21: 111. 10. Burstein VL, Guasconi L, Beccacece I et al. IL-17-mediated immunity controls skin infection and T helper 1 response during experimental Microsporum canis dermatophytosis. J. Invest. Derm. 2018; 138: 1744–53. 11. Sparber F, LeibundGut-Landmann S. Interleukin-17 in antifungal immunity. Pathogens 2019; 8: 54.